Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field
Av Korbinian Löbmann is the Chief Scientific Officer and co-founder of the Danish company Zerion Pharma, which is a spin-out from the University of Copenhagen. On May 14th, when New Updates in Drug Formulation & Bioavailability is held for the 13th time, he will be the moderator.
What are you most looking forward to in this year's edition of New Updates in Drug Formulation & Bioavailability?
”I am looking forward to moderating an exciting conference that captures the (mainly but not exclusively) Nordic industry within drug formulation and bioavailability. It is quite a specialized area and it is great to see so much activity in this area. The program promises new insights into different formulation approaches and covers academic and industrial speakers. I believe it will generate interest among a broad audience. The speakers are the best in their fields and of high quality, and we have both new speakers at the symposium as well as returning speakers from previous editions. I look forward to learn many new insights and also to see the progress and developments within the industry, especially those from the returning speakers. Of course, I also look forward to meet the speakers and conference participants in person, having the opportunity to listen and discuss with them”.
What are you working on yourself right now?
”At Zerion, we have developed the unique and powerful technology platform Dispersome that allows the development of highly soluble and bioavailable drug formulations. The Dispersome® technology is based on using the protein beta-lactoglobulin (BLG) as novel pharmaceutical excipient. Increasing drug solubility by applying the Dispersome® technology results in enhanced oral bioavailability, lower drug dosing and better formulations. In turn, this increases the chance of success for developing more new drugs into commercial products and allows for improvement of existing drugs, providing competitive alternative solutions with clear patient benefits. We are very active in promoting and commercializing our technology and for this we work with partner companies both from the innovator and generic sector. Through one of our partner companies, we have a clinical study upcoming this year, which is a very exciting and important milestone for us.”
New Updates in Drug Formulation & Bioavailability
The event is held Copenhagen on May 14. Read more: formulationsbioavailability.com
Artikeln är en del av vårt tema om News in English.